How Can a High-Performance Screening Strategy Be Determined for Cervical Cancer Prevention? Evidence From a Hierarchical Clustering Analysis of a Multicentric Clinical Study
Heling Bao(Chinese Academy of Medical Sciences & Peking Union Medical College), Lınhong Wang(Chinese Center For Disease Control and Prevention), Haijun Wang(Hebei Medical University), Xiaosong Zhang(Pfizer (United States)), Hui Bi(Peking University), Yun Zhao(Tumor Hospital of Guangxi Medical University), Liwen Fang(Chinese Center For Disease Control and Prevention)
Cited by 5
Related Papers
Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
|The Lancet|2019|3.8k
A Lancet Commission on 70 years of women's reproductive, maternal, newborn, child, and adolescent health in China
|The Lancet|2021|579
Chronic obstructive pulmonary disease in China: a nationwide prevalence study
|The Lancet Respiratory Medicine|2018|490
Prevalence of Liver Steatosis and Fibrosis in the General Population and Various High-Risk Populations: A Nationwide Study With 5.7 Million Adults in China
|Gastroenterology|2023|213
Breast Cancer Screening Rates Among Women Aged 20 Years and Above — China, 2015
|China CDC Weekly|2021|121